Dianthus Therapeutics Stock Analysis
DNTH Stock | 23.83 0.03 0.13% |
Dianthus Therapeutics is overvalued with Real Value of 20.54 and Target Price of 24.0. The main objective of Dianthus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dianthus Therapeutics is worth, separate from its market price. There are two main types of Dianthus Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dianthus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Dianthus Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Dianthus |
Dianthus Stock Analysis Notes
About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Dianthus Therapeutics was currently reported as 11.51. The company recorded earning per share (EPS) of 7.22. Dianthus Therapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 12th of September 2023. To learn more about Dianthus Therapeutics call Marino MBA at 929 999 4055 or check out https://dianthustx.com.Dianthus Therapeutics Quarterly Total Revenue |
|
Dianthus Therapeutics Investment Alerts
Dianthus Therapeutics generated a negative expected return over the last 90 days | |
Dianthus Therapeutics has high historical volatility and very poor performance | |
Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 2.83 M. Net Loss for the year was (43.55 M) with profit before overhead, payroll, taxes, and interest of 6.42 M. | |
Dianthus Therapeutics generates negative cash flow from operations | |
Over 91.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from investing.com: Oppenheimer sees upside in Dianthus as CIDP study gains FDA support |
Dianthus Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dianthus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
8th of February 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
8th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Dianthus Largest EPS Surprises
Earnings surprises can significantly impact Dianthus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-08-04 | 2022-06-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2021-08-05 | 2021-06-30 | -0.3725 | -0.32 | 0.0525 | 14 | ||
2020-11-05 | 2020-09-30 | -0.43 | -0.37 | 0.06 | 13 |
Dianthus Therapeutics Environmental, Social, and Governance (ESG) Scores
Dianthus Therapeutics' ESG score is a quantitative measure that evaluates Dianthus Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Dianthus Therapeutics' operations that may have significant financial implications and affect Dianthus Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Dianthus Therapeutics Thematic Classifications
In addition to having Dianthus Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Dianthus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 705.3 M.Dianthus Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.24) | (0.25) | |
Return On Capital Employed | (0.28) | (0.30) | |
Return On Assets | (0.24) | (0.25) | |
Return On Equity | (0.26) | (0.27) |
Management Efficiency
Dianthus Therapeutics has return on total asset (ROA) of (0.1896) % which means that it has lost $0.1896 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2599) %, meaning that it created substantial loss on money invested by shareholders. Dianthus Therapeutics' management efficiency ratios could be used to measure how well Dianthus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.25. The current Return On Capital Employed is estimated to decrease to -0.3. As of now, Dianthus Therapeutics' Non Currrent Assets Other are increasing as compared to previous years. The Dianthus Therapeutics' current Other Assets is estimated to increase to about 146.1 K, while Total Assets are projected to decrease to under 112.5 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 32.77 | 38.91 | |
Tangible Book Value Per Share | 32.77 | 38.91 | |
Enterprise Value Over EBITDA | 1.62 | 1.70 | |
Price Book Value Ratio | 0.32 | 0.30 | |
Enterprise Value Multiple | 1.62 | 1.70 | |
Price Fair Value | 0.32 | 0.30 | |
Enterprise Value | -78.1 M | -74.2 M |
Understanding the operational decisions made by Dianthus Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin (13.77) | Return On Assets (0.19) | Return On Equity (0.26) |
Technical Drivers
As of the 29th of November, Dianthus Therapeutics shows the Coefficient Of Variation of (1,863), standard deviation of 3.83, and Mean Deviation of 2.81. Dianthus Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Dianthus Therapeutics Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Dianthus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Dianthus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Dianthus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dianthus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dianthus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dianthus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dianthus Therapeutics Predictive Daily Indicators
Dianthus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dianthus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Dianthus Therapeutics Corporate Filings
13A | 22nd of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
21st of October 2024 Other Reports | ViewVerify | |
11th of October 2024 Other Reports | ViewVerify | |
1st of October 2024 Other Reports | ViewVerify |
Dianthus Therapeutics Forecast Models
Dianthus Therapeutics' time-series forecasting models are one of many Dianthus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dianthus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Dianthus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Dianthus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dianthus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dianthus Therapeutics. By using and applying Dianthus Stock analysis, traders can create a robust methodology for identifying Dianthus entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (15.41) | (16.18) | |
Operating Profit Margin | (17.05) | (17.90) | |
Net Loss | (15.41) | (16.18) | |
Gross Profit Margin | 0.87 | 0.92 |
Current Dianthus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dianthus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dianthus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
24.0 | Strong Buy | 11 | Odds |
Most Dianthus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dianthus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dianthus Therapeutics, talking to its executives and customers, or listening to Dianthus conference calls.
Dianthus Stock Analysis Indicators
Dianthus Therapeutics stock analysis indicators help investors evaluate how Dianthus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dianthus Therapeutics shares will generate the highest return on investment. By understating and applying Dianthus Therapeutics stock analysis, traders can identify Dianthus Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 15.4 M | |
Common Stock Shares Outstanding | 5.2 M | |
Total Stockholder Equity | 168.9 M | |
Property Plant And Equipment Net | 800 K | |
Cash And Short Term Investments | 173.7 M | |
Cash | 132.3 M | |
Accounts Payable | 2.6 M | |
Net Debt | -131.7 M | |
50 Day M A | 26.8238 | |
Total Current Liabilities | 9.6 M | |
Other Operating Expenses | 51 M | |
Non Current Assets Total | 2 M | |
Non Currrent Assets Other | 1.1 M | |
Stock Based Compensation | 2.9 M |
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |